At the time of his application, Dr. Pavan Bendapudi was finishing his third year of adult hematology/oncology training at the combined Dana Farber Cancer Institute- Massachusetts General Hospital (DFCI-MGH) fellowship program. After finishing his…
Bleeding.org ConversationsEach month, we’re sitting down with the experts in our community for some real talk. Hosted by actor and advocate Greg Grunberg, Bleeding.org Conversations features discussions with lived experience experts…
Speakers: Glaivy Batsuli, MD; Nikole Scappe-HagenIron deficiency -- with or without anemia -- is common in people with bleeding disorders, but there has been no standardized guidance for screening. This has now changed with the release of NBDF's…
In a letter sent to healthcare providers, Ferring Pharmaceuticals announced that STIMATE® (desmopressin acetate) nasal spray is expected to be available in the United States beginning October 2026.STIMATE was voluntarily recalled in July of 2020 due…
CSL Behring, the biopharmaceutical company behind the hemophilia B gene therapy HEMGENIX ® (etranacogene dezaparvovec-drlb), provided an update to the bleeding disorders community regarding the availability of the treatment. In a letter to the…
The treatment landscape of hemophilia A care continues to rapidly evolve. This webinar will explore Genentech's latest research and share updates on investigational treatments currently in development, including a FVIII mimetic and a gene therapy.…
Join NBDF online as we convene stakeholders from across the community to work together to improve health outcomes for women & girls with bleeding disorders. At these semiannual interactive meetings, we invite all stakeholders to share updates on…
Federal: Funding for Fiscal Year 2027Trying to prevent a fight over federal spending and potential partial government shutdown before the mid-term election, the House passed a continuing resolution (CR) to fund…
Guest Speaker: Phil Gattone, CEO NBDF